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Hyphema. Part II. Diagnosis and Treatment
Abstract
The clinical appearance of hyphema is variable and is influenced by the volume of blood and the amount of
time erythrocytes are present in the anterior chamber. When hyphema is evident, a complete history should
be obtained and a thorough physical examination performed to direct the initial selection of diagnostic tests.
Secondary complications of hyphema include glaucoma, synechiae, cataract formation, blood-staining of the
cornea, and blindness. Frequent measurement of intraocular pressure is recommended. The two primary
management issues in animals with hyphema are prevention of secondary hemorrhage (by treating the
underlying disease) and control of secondary glaucoma.
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FOCAL POINT 
Hyphema is frequently associated 
with iridocyclitis and generally 
implies severe intraocular or 
systemic disease. 
KEY FACTS 
The prognosis for animals with 
hyphema depends in large part 
on the identification of underlying 
diseases; institution of proper 
treatment; and careful , long-term 
follow-up, p. 74. 
Athorough ophthalmic and 
systemic diagnostic evaluation 
should be performed when 
hyphema is present, p. 75. 
The two primary management 
issues in animals with hyphema 
are preventing secondary 
hemorrhage (i.e., rebleeding) 
and controlling secondary 
glaucoma, 77. 
Frequent measurement of 
intraocular pressure is required 
in patients with hyphema, p. 78. 
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ABSTRACT: The clinical appearance of hyphemais variable and is influenced by the volume of e1im 
blood and the amount of time erythrocytes are present in the anterior chamber. When hyphe­ pruc 
ma is evident, a complete history should be obtained and a thorough physical examination that 
performed to direct the initial selection of diagnostic tests. Secondary complications of hyphe­ ocul 
ma include glaucoma, synechiae, cataract formation , blood-staining of the cornea, and blind­ 109 
ness. Frequent measurement of intraocular pressure is recommended. The two primary man­ unn 
agement issues in animals with hyphema are prevention of secondary hemorrhage (by ougr
treating the underlying di.sease) and control of secondary glaucoma. 
P
amll 
tect 
syste art I of this two-part presentation reviewed the pathophysiologic mecha­
orrhnisms that most frequently result in hyphema in animals; this article cov­
braners diagnostic and treatment considerations. The prognosis for animals 
with hyphema depends on identifYing the underlying cause; initiating proper muo 
sa) ( treatment; and careful, long-term follow-up. 
sent 
tope 
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HISTORY 
When hyphema is evident, a complete history should be obtained and a thor~ 
IrIS Iough physica.l examination performed to direct the ,initial selection of appropriate 
hyp ldiagnostic tests. Recent health and vaccination statlls should also be ascertained. 
Abd,Trauma or ingestion of toxins (e.g., anticoagulant todenticide) should be consid­
tionered if an animal has access to the outdoors regardless of whether a traumatic in­
vealcident or rodenticide ingestion was witnessed by the owner. Living in or travel to 
a thregiom in which enzootic infectious disease (e.g., ehrlichiosis, Rocky Mountain 
rhagspotted fever) is common should alert clinicians to consider infectious agents as a 
men'potential cause of hyphema. Recent drug administration or past illness may be 
tivel)important factors in determining the cause of hyphema. A recent history of ab­
intr.normal vision or behavior before the onset of hyphema may signifY preexisting or 
shouunderlying ocular (e .g., iridocyclitis , glaucoma, retinal detachment) or central 
iden!nervous system (e.g. , hemorrhage, retrobu1bar optic neuriris) disease. Hisrory of 
*Parr I of this [Wo-parr presentation appeared in the November 1999 (Vol. 21 >No. 11 ) OPH 
issue of Compendium. Tf: 
I 
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recurrent hyphema is suggestive detailed ophthalmic examina­
of a persistent ocular or system­ tion of both the anterior and 
ic disease. posterior segments of the af­
The time at which hyphema fected and contralateral eye. In­
is first observed may also assist direct pupillary light response 
clinicians in developing a list of allows the evaluation of retinal 
differential considerations. For function, even with a blood­
example, hyphema from anti­ filled anterior chamber, as long 
coagulant rodenticide toxicity as the contralateral pupil is vis­
takes 5 to 7 days to develop, ible. Iridocyclitis manifests as 
whereas hemorrhage occurs im­ conjunctivitis, corneal edema, 
mediately in patients with ocu­ miosis, and hyporony. Glauco­
lar trauma. Ocular neoplasia may ma and retinal detachment areFigure 1A 
also cause an acute onset of hy­ generally associated with a my­
phema. driatic pupil. When hyphema2 
is aruibutable to a systemic dis­3PHYSICAL EXAMINATION ease process, the contralateral 
The physical examination of eye may also have clinical sigll:s 
an animal with hyphema should suggestive of the disease. Fun­
not be limited only ro the affect­ 1 duscopic examination allows 
ed eye. \Vhen trauma has been direct visualization of delicate 
eliminated as a likely cause, the vascular structures (retinal and 
prudent approach is ro assume choroidal vasculature) and cen­
that a serious sight-threatening tral nervous tissue (optic nerve 
ocular disease or life-rhreaten­ head, retina). Ocular signs sug­
ing systemic disease is present gestive of systemic vasculitis are 
until proven otherwise. A thor- Figure 1B frequently detected during ex­
ough and detailed physical ex­ Figure 1-Photograph (A) and photomicrograph (B) amination of the fundus. 
amination is indicated to de­ showing inrrastromal hemorrhage of rhe iris (1) in a Depending on the cause and 
tect any underlying evidence of dog (cornea (2J, anterior chamber (3J, posrerior cham­ severity of blood-ocular barrier 
systemic disease. Petechial hem­ ber (4j). (Hematoxylin & eosin srain; original magni­ breakdown and the presence of 
orrhages of the mucous mem­ iridocyclitis, aqueous flare (pre­ficarion, x40) 
branes (i.e., conjunctiva, oral dominantly proteins), hypopy­
mucosa, preputial/vulvar m uco­ on, or hyphema may appear in 
sa) or skin are frequently pre­ the anterior chamber. The clin­
sent along with thrombocy­ ical appearance of hyphema is 
topenia or thrombocytopathy. influenced by the volume of 
Intrastromal hemorrhage of the erythrocytes in the anterior 
iris may also be present before chamber and by how long they 
hyphema occurs (Figure 1). have been present and may dif­
Abdominal and thoracic palpa­ fer substantially from case to 
tion and auscultation may re­ case. The term complete or to­
veal physical signs suggestive of tal h),phema is used to describe 
a third-compartment hemor- hemorrhage filling the entire 
anterior chamber and is usuallyrhage or vital organ involve- Figure 2-Complere (toral) hyphema in a dog. 
memo Unless trauma is defmi- a result of acute fulminant or 
tively identified as the cause of recurrent hemorrhage (Figure 2). 
intraocular hemorrhage, every cat with hyphema Complete hyphema obstructs the examiner's ability to 
should have its arterial blood pressure measured to visualize intraocular structures. 
identify systemic hyperrension. 1 The blood in a complete hyphema may change color 
from red to black as a result of altered aqueous dynam­
OPHTHALMIC EXAMINATION ics, indicating the cessation of aqueous circulation. 2 If 
The physical examination should always include a hemorrhage was initially minimal and transitory, hy-
I R I DOCYC LlTI S FUNDUSCOPIC EXAMINATION . COMPLETE HYPHEMA 
l 
l 
I 
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phema is light red in appear­
ance. This type of hyphema may 
develop a shallow line of demar­
cation (i.e. , gravity line) when 
erythrocytes settle due to gravity 
in a homogeneous layer in the 
ventral anterior chamber (Figure 
3). Extensive or persistent hem­
orrhageinto the anterior cham­
ber appears bright red in color 
and may occlude both the pupil 
and iris. Complete hyphema at­
tributable to transient hemor­
rhage that has been present for 
at least 5 to 7 days appears dark 
red or bluish-black and is re­
ferred to as eight-baff hyphema 
(Figure 4) ..1 Decreased oxygena­
tion of erythrocytes in the ante­
rior chamber is reflected by the 
dark color. 2 Chronic active hy­
phema may appear light or dark 
red or bluish-black, depending 
on when the last active hemor­
rhage occurred. Occlusion of the 
pupil by hyphema may cause a 
relative pupillary block that in­
hibits aqueous circulation to the 
anterior chamber, resulting in 
subsequent elevated intraocular 
pressure (lOP). 
There are definitive circum­
stances thac determine when 
blood in the anterior chamber 
mayor may not clot. Hyphema 
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currently (e.g., bone-marrow dis­
ease). If bone-marrow disease is 
suspected based on CBC results, 
aspiration cytology with or with­
out core biopsy is indicated. 4 
Serum biochemical profile and 
urinalysis may help identify such 
underlying abnormalities as liver 
disease, renal insufficiency, or hy­
peradrenocorticism. 
Indications for selecting more 
specific diagnostic tests are de­
termined by history, physical ex-
3.mination findings, and initial 
diagnostic test results. Evalua­
tion for infectious diseases should 
Figure 3-Hyphema wirh gravity line. Eryrhrocytes be performed if suggested by ge­

sertle due (0 gravity in a homogeneous layer in rhe ographic location, travel history, 

ventral anterior chamber. or exposure to other risk factors. 

Toxoplasma gondii, feline leukemia 

virus (FeLV), feline immuno­

deficiency virus (FIV), and FIP 

infection and possibly systemic 

fungal diseases should be consid­

ered when hyphema is evident ,in 

a cat. 5 The seroprevalence of T 

gondii in cats with iridocyclitis 

was reported to be as high as 

78.5%.5 However, serologic evi­

dence of infection by T gondii, 

FeLV, FIV, or FIP does not nec­

Figure 4-Dark red or bluish-black appearance of essarily correlate with clinical 

eighr-ball hyphema. disease induced by these causa­
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caused by trauma, vasculitis (e.g., feline infectious peri­
tonitis [FIP]), or iridocycliris may clot, whereas hyphe­
rna attributable to immune-mediated thrombocytope­
nia or warfarin toxicity generally will not dot. '! 
Hyphema attributable to rubeosis iridis (new vascular 
proliferation of the iris), intraocular neoplasia, or con­
genital ocular anomalies may occasionally clot." 
EXPANDED DATABASE 
Laboratory tests should be performed based on find­
ings from the history and physical examination. A di­
rect blood smear permits rapid estimation of platelet 
and megathrombocyte numbers and the detection of 
erythrocyte and leukocyte involvement (e.g., presence 
of schistocyrosis or Haemobartonella). Platelets, leuko­
cytes, and erythrocytes should be evaluated by a com­
plete blood count (CBC); the three cell lines may be af­
fected individually (e.g., thrombocytopenia) or con-
bleeding disorder is suspected, a 
coagulat,ion profile should be completed.4 
Sampling of aqueous humor to determine local in­
traocular antibody production is not ,indicated in pa­
tients with hyphema because the sample will be con­
taminated with systemic blood. When hyphema 
prevents visualization of intraocular structures, 
transcorneal B-mode ultrasound (7.5- to 12-MHz 
transducer) is indicated to determine whether retinal 
detachment or intraocular tumors are present or to 
identify other oCLIlar lesions (e.g., luxated lens, intraoc­
ular foreign body).G Skull radiographs, computed to­
mography, or magnetic resonance imaging may also re­
veal an intraocular foreign body, depending on the 
type or composite. When a metallic intraocular foreign 
body is suspected, magnetic resonance imaging should 
be avoided and computed tomography performed. 
Retinal function can be evaluated using electroretinog­
raphy.7 
EIGHT-BALL HYPHEMA INFECTIOUS DISEASES IMAGING TECHNIQUES 
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TREATMENT 
Primary management issues in animals with hyphe­
rna include preventing secondary hemorrhage (i.e., re­
bleeding) by (1) treating the underlying disease, (2) 
treating iridocyclitis, and (3) controlling secondary 
glaucoma (Table I). There is considerable variation 
among specific treatment regimens to eliminate blood 
from the anterior chamber, bur the hallmark of hyphe­
rna treatment is management of the iridocyclitis that is 
frequently present. Erythrocytes exit the anterior cham­
ber primarily through the iridocorneal dra,inage angle. 
The iris produces enough fibrinolytic enzymes in most 
instances to prevent blood from cloning so that it can 
more easily exit the anterior chamber via the aqueous 
humor outflow pathways. Uncomplicated hyphema 
should resolve within 7 to 21 days.3 Hyphema that 
TABLE I 

Treatment of Hyphema".IJ 

Disorder 
Iridocyclitis)' 
Blood or fibrin clot \9 
Secondary glaucoma' O .11 
"See rexr for derails. 
Drug Class 
Topical parasympatholytics 
Topical corticosteroids 
Topical NSAIDs 
y temic corticosteroids 
Systemic NSAIDs 
Fibrinolytics 
Systemic carbonic 
anhydrase inhibitors 
Topical carbonic 
anhydrase inhibitors 
Topical sympathomimetic 
drugs 
Topical sympatholytic 
drugs 
Osmotic agents 
Drug 
Atropine 1% (use ointment 

in cats) 

Prednisolone acetate suspension 

1%, dexamethasone solution 0.1 % 

Dexamethasone ointment 0.05% 
Flurbiprofen 0.03%, suprofen 1 %, 
indomethacin 1%, diclofenac 0.1 % 
Prednisone 
Aspirin 
Flunixin meglumine 
Carprofen 
Tissue plasminogen activator 
Dichlorphenamide 
Methazolamide 
Dorzolamide 3% 
Epinephrine 1%, 
dipivefrin HCI 0.1 % 
T imolol maleate 0.5% 
Mannitol 
"Underlying diseases should be rreared firsr in cases ofhyphema. 
IV = inrravenously; PO =orally. 
Frequency/Dose 
1-4 times daily 
4-6 times daily 
3-4 times daily 
4 times daily 
1-2 mg/kg/day in 
divided doses 
Dogs: 10-15 mg/kg PO 
2-3 times daily 
Cats: 80 mg PO every 
48-72 hr 
Dogs: 0.25-0.5 mg/kg 
IV, single dose 
Dogs: 2 mg/kg PO 
t\vice daily 
25-75 flg intracamerally 
Dogs: 2-4 mg/kg PO 
2-3 times daily 
Cats: 1 mg/kg PO 2-3 
times daily 
2-4 mg/kg PO 2-3 
times daily 
3 times daily 
2-3 times daily 
2-3 times daily 
0.5-1.0 g/kg IV 
I 
I 
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continues to bleed may indicate that the underlying 
disease is still present. Surgical removal of a blood clot 
with or without iridectomy is discussed in the human 
medicalliterature2•12 and is rarely necessary in human or 
veterinary patients. 
Prevention of a posterior synechiae and iris bombe is 
achieved with the use of topical parasympatholytics 
(e.g., atropine) to dilate the pupil and topical cortico­
steroids to suppress anrerior uveitis (Table I). In addi­
tion to prevenring synechiae, topical atropine (a topical 
mydriatic and cycloplegic drug) also relieves some pain 
associated with spasm of the ciliary musculature and 
helps to stabilize the blood-aqueous barrier. I.I- 1> If an 
increase in lOP is noted after the initiation of mydriat­
ic treatment, atropine should be discontinued immedi­
ately and glaucoma treatment initiated.' 
Topical use of parasympathomimetic drugs (e.g., pi­
locarpine) to treat hyphema has been advocated to con­
tract the ciliary musde, which hypothetically facilitates 
drainage of blood from the anrerior chamber through 
the iridocorneal angle. I !; Parasympathomimetic drugs 
also cause miosis, which increases iris surface area, 
thereby hypothetically exposing iris surface fibri­
nolysins to the clot and blood in the anrerior cham­
ber. 1(. We do not recommend using topical parasympa­
thomimetic drugs to treat hyphema; they dilate iris 
blood vessels and increase iridal intravascular pressure, 
which may exacerbate hyphema. Because these drugs 
induce miosis, the risk of posterior synechiae forma­
tion, iris bombe, and peripheral anrerior synechiae for­
mation is increased. 
Nonspecific reduction of ocular inflammation to pre­
serve the transparency and function of ocular structures 
and stabilize the blood-aqueous barrier can be achieved 
with topical corticosteroids andlor NSAIDs (Table 
I). Ll.1 7 Topical corticosteroids are contraindicated when 
corneal ulceration is present. Systemic administration 
of NSAIDs can further decrease inflammation but 
should also be used very cautiously because of their in­
terference with platelet function. Systemic cortico­
steroids (e.g., prednisone, prednisolone) should be used 
cautiously and only when systemic infectious disease 
has been ruled out or is being treated concurrently. Sys­
temic immunosuppressive doses of corticosteroids and 
systemic carbonic anhydrase inhibitors may help to 
reattach retinas in patients w·ith exudative detach­
ments. IH.l~ 
Although the use of anrifibrinolytic agents in the 
managemenr of hyphema is conrroversial, intracameral 
injection of tissue plasminogen activator (tPA) to in­
duce fibrinolysis can be performed to reverse a pupil­
lary block when the iris is adhered to the lens by a 
blood or fibrin clot (Table I) ..1.~. 12 tPA is most effective 
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when injected within 48 hours of clot formation, but it 
can also be effective tn dissolving clots of longer dura­
tion. ' However, tPA injections may also induce hyphe­
rna or result in more severe hyphema from dissolution 
of a blood clot when given within 24 hours of the ini­
tial hemorrhage or when recurrent bleeding is Iikely..19 
Surgical intervention and concurrent systemic and 
topical treatment with antibiotics should be considered 
when hyphema results from penetrating ocular injury 
or blunt trauma with eyeball rupture. Restricted exer­
cise or even cage rest is recommended to prevent re­
bleeding. Animals with hyphema may need to be hos­
pitalized for close monitoring of possible secondary 
hemorrhages and elevation of rOp. lOP should be mea­
sured at least daily during the hospital stay a'nd fre­
quently after discharge. 12 ,IG We do not recommend 
Schiotz tonometry in animals with weakened corneas 
caused by penetrating trauma. 
If secondary glaucoma develops due to anterior or 
posterior synechiae of the iris , treatment can be at­
tempted (e.g., intracameral tPA and antiglaucoma 
drugs) but the prognosis to save vision is poor. When 
the eyeball is irreversibly blind or painful from sec­
ondary glaucoma, enucleation should be performed. 
Medical treatment of secondary glaucoma consists of a 
combination of systemic or topical carbonic anhydrase 
inhibitors, topical sympathomimetic drugs, and sympa­
tholytic drugs (Table I). Osmotic agents are less effec­
tive with a leaky blood-ocular barrier. Because of the 
risk of posterior synechiae, parasympathomimetic drugs 
(e.g., pilocarpine) are contraindicated. 
COMPLICATIONS 
Mild hyphema may resolve without significant se­
quelae. The main complications of persistent hyphema 
are increased lOP, peripheral anterior and posterior 
synechiae, development of cataracts, and an increased 
risk of corneal blood staining attributable to endothe­
lial damage and breaks in Descemet's membrane. 12 If an 
underlying disease persists and hemorrhage is recurrent, 
atrophy of the eyeball (phthisis bulbi) and blindness are 
usually the long-term results. 
PROGNOSIS 
Prognosis for vision in geriatric dogs with hyphema 
secondary to retinal disease is grave, 20 In cases of unex­
plained, unresponsive, or recurring hyphema, the diag­
nosis must be reassessed. Prognosis is grave for any hy­
phema in which an unknown underlying systemic 
disease persists. In such cases, enucleation is recom­
mended if the lOP rises to leve'ls that cause pain. When 
intraocular neoplasia is known or strongly suspected as 
the cause for hyphema, the affected eye should be enu­
clea 
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cleared and submiued for histopathologic evaluation. l 
If the underlying cause is nonrec urring or treated and 
lOP does nor increase, an accurate prognosis for return 
of the eye to cosmetic and visual normalcy can be made 
once resorption of the hemorrhage allows a complete 
intraocular examination ..' It is difficult to predict wheth­
er hyphema will resorb. 
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ARTICLE #4 CE TEST 
The article you have read qualifies for 1.5 con­
tac t hours of C ontinuing Education Credit from 
the Auburn Unive rsity College of Veterinary 
M edici ne. Choose only the onl! best answer to each 
of the following questions; then mark your an­
swers on the test form inserted in Compendium. 
1. 	 The dark red or bluish-black color of eight-ball hyphe­
ma indicates decreased 
a. 	 oxygenation of the animal. 
b. ocular b:lood flow. 
e. 	 oxygenarion of erythrocytes in rhe antnior chamber. 
d. 	 none of the above 
2. 	 Which of the following must be co nsidered 111 cats 
with intraocular hemo rrhage? 
a. FIr 

b, sysremic hypertension 

e. T gondii 

d , all of the ahove 

3. 	Sampling of aqueous humor from an eye with hyphe­
m<1 to derermine intraocular antibody producrion 15 
not indicared because 
a. 	 rhere is no inrraocular anribody producrion , 
h. 	 the aqueous humor is conraminared wirh antibod­
ies from sysremic circularion, 
c. 	 possible complicarions (e.g., a dramaric drop in lOP) . 
d, 	Sampling of aqueous humo r is indicared in eyes 
with hyphema. 
(COilTin lies on page 90) 
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Hyphema (r:u lllinuedfro/1l.page 79) 
4 . 	When hyphema is presenr, a complete hisrory should 
include questions regardi ng 
:l. geographic location of res idencelrravel history. 
b. 	recent admin is tratio n of medicati on. 
c. 	 pas t illnesseslrecenr visual impairment. 
d. 	 all of th e above 
5. 	In an eye with hyphema, the condition of the re[Ina 
can be assessed with 
a. 	 indirect pupillary light respo nse (if the contralateral 
pupil is vis ible). 
b . 	transcorneal B-mode ultrasound. 
c. 	 elect roretinography. 
d. 	 all of the above 
6. 	_______ is not caused by topical atropine. 

:l. Mydriasis 

b. 	Cycloplegia 
c. 	 Mios is 
d. 	 Stab ilization of the blood-aqueous barrier 
7 . 	Use of topical corticosteroids is contraindicated in pa­
tiems with . . . 
a. 	 antenor UV CltlS. c. corneal ulcer. 
b. 	 cataract. d. conjunc[Ivltls. 
8. 	 How fas t does uncomplicated hyphema generally resolve? 
a. 	 1 day c. 3 months 
b. 	 7 to 2 1 days d. 6 monrhs 
9. is no t a complication of hyphema. 
a. 	Optic neu ritis 
b. 	 G laucoma 
c. 	 Anterio r and posterior synechiae of the iris 
d. 	Corneal blood staining 
lO. should nor be used to trea t iridocyclitis. 
<l. 	 T opical pilocarpine 
b. 	 T opical atropi ne 
c. 	 T opical prednisolone acetate 
d. Systemic prednisolone 
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